Published online Feb 6, 2017. doi: 10.5315/wjh.v6.i1.1
Peer-review started: August 24, 2016
First decision: October 20, 2016
Revised: October 21, 2016
Accepted: January 2, 2017
Article in press: January 3, 2017
Published online: February 6, 2017
Core tip: Tyrosine kinase inhibitors (TKIs) have changed the fatal outcomes of chronic myeloid leukemia (CML). Many studies showed that TKIs provided rapid response, few serious adverse event and impressive survival outcomes. Although, allogeneic stem cell transplantation (ASCT) is only curative treatment option for CML, since 1999, the numbers of ASCT have dropped. Currently, ASCT is offering for patients who are resistant or intolerant to at least one second generation TKI or for patients with blastic phase. Here, we present our center’s outcomes of ASCT for patients with CML and then, we discuss the place of ASCT in CML treatment in the TKIs era.